RIP kinase

RIP kinase Related Products (84):

By Effects:	Control (1) Inhibitors (76) Activators (6) Degrader (1)

Cat. No.	Product Name	Effect	Purity

HY-15760

Necrostatin-1	Inhibitor	99.89%
Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC₅₀ of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC₅₀=182 nM). Necrostatin-1 is also an IDO inhibitor.

HY-144828

RIP1/RIP3/MLKL activator 1	Activator
RIP1/RIP3/MLKL activator 1 (Compound 6i) is a potent anti-glioma agent. RIP1/RIP3/MLKL activator 1 induces necroptosis through RIP1/RIP3/MLKL pathway. RIP1/RIP3/MLKL activator 1 exerts acceptable BBB permeability.

HY-100339

GSK583	Inhibitor	99.93%
GSK583 is a highly potent, orally active and selective inhibitor of RIP2 Kinase, with IC₅₀ of 5 nM. GSK583 inhibits both TNF-α and IL-6 production with an IC₅₀ value of 200 nM.

HY-101760

GSK2982772	Inhibitor	99.79%
GSK2982772 is a potent, orally active and ATP competitive RIP1 kinase inhibitor with IC₅₀ values of 16 nM and 20 nM for human and monkey RIP1, respectively.

HY-104021

GSK840	Inhibitor	98.01%
GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 0.9 nM, and inhibits kinase activity with an IC₅₀ of 0.3 nM.

HY-169509

Topoisomerase I/II inhibitor 8	Activator
Topoisomerase I/II Inhibitor 8 (Compound Ru7) is a dual catalytic inhibitor of Topoisomerase I/II, capable of inducing DNA damage and PARP-1 activation, which subsequently leads to the activation of RIPK1, RIPK3, and MLKL, ultimately triggering necroptosis. Topoisomerase I/II Inhibitor 8 demonstrates remarkable anticancer activity by effectively targeting the nuclei of cancer cells and inducing cell death through necroptosis, showing great clinical potential in circumventing drug resistance in cancer treatment.

HY-153598

LD4172	Degrader
LD4172 is a PROTAC degrader for RIP kinase (RIPK1) with DC₅₀ in nanomolare levels. LD4172 induces apoptosis in cell B16F10 with combination of TNF-α. LD4172 exhibits antitumor efficacy in mouse models. (Pink: ligand for target protein (HY-170613); Black: linker (HY-W012241); Blue: ligand for E3 ligase VHL (HY-112078))

HY-170544

RIPK1-IN-28	Inhibitor
RIPK1-IN-28 (compound 13) is an orally active RIPK1 inhibitor. RIPK1-IN-28 inhibits human I2.1 and Hepa1‐6 cells with IC₅₀s of 0.4 and 1.2 nM, respectively.

HY-B0339

Primidone	Inhibitor	99.96%
Primidone is the orally active inhibitor for TRPM3 (IC₅₀ = 0.6 μM), RIP kinase and voltage-gated sodium channel, and the antagonist for GABA receptor. Primidone can be used as the analgesic and anticonvulsant agent.

HY-101032

RIPA-56	Inhibitor	99.94%
RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC₅₀ of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome.

HY-103028A

GSK963	Inhibitor	98.24%
GSK963 is a chiral, highly potent and selective inhibitor of RIP1 kinase, with an IC₅₀ of 29 nM. GSK963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro.

HY-114492

GSK547	Inhibitor	99.92%
GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer.

HY-122909

GSK2593074A	Inhibitor	99.07%
GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3.

HY-114349

HS-1371	Inhibitor	99.89%
HS-1371 is a potent and ATP-competitive receptor-interacting protein kinase 3 (RIP3) inhibitor with an IC₅₀ of 20.8 nM.

HY-107978

RIPK-IN-4	Inhibitor	99.71%
RIPK-IN-4 is a potent and selective RIPK2 inhibitor with excellent oral bioavailability, and has an IC₅₀ of 3 nM.

HY-111946

GSK3145095	Inhibitor	99.39%
GSK3145095 is a RIP1 kinase inhibitor with an IC₅₀ of 6.3 nM .

HY-119933

RIPK1-IN-7	Inhibitor	98.56%
RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a K_d of 4 nM and an enzymatic IC₅₀ of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model.

HY-135826

Necroptosis-IN-1	Inhibitor	98.60%
Necroptosis-IN-1, an analog of Necrostatin-1, is a potent necroptosis inhibitor. Necroptosis-IN-1 is a RIPK inhibitor.

HY-100131

GSK481	Inhibitor	98.57%
GSK481 is a highly potent, selective, and specific receptor interacting protein 1 (RIP1) kinase inhibitor with an IC₅₀ of 1.3 nM, which inhibits Ser¹⁶⁶ phosphorylation in wild-type human RIP1 (IC₅₀=2.8 nM). GSK481 also exhibits excellent translation in the U937 cellular assay with an IC₅₀ of 10 nM.

HY-111409

RIP1 kinase inhibitor 1	Inhibitor	99.96%
RIP1 kinase inhibitor 1 (compound 22) is a highly potent, orally available, and brain-penetrating RIP1 kinase inhibitor (pK_i=9.04).

Name
Email *

	Sorry, but the email address you supplied was invalid.